Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sibeprenlimab in Sjögren's disease
NCT06928142Phase 2Active, not recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of sibeprenlimab in Sjögren's syndrome, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Apr 2025; status: active, not recruiting.
02
Drugs
sibeprenlimab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT06928142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06928142.